A Phase II Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.

Trial Profile

A Phase II Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2013

At a glance

  • Drugs Decitabine (Primary) ; Gemtuzumab ozogamicin (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Aug 2012 Actual end date Aug 2012 added as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Apr 2012 Planned end date changed from 1 Apr 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top